An Enhancer-Driven Stem Cell–Like Program Mediated by SOX9 Blocks Intestinal Differentiation in Colorectal Cancer

• DOI: 10.1053/j.gastro.2021.09.044
• Publication Date: 2021-09-27T05:15:17Z
• Authors: Xiaoyan Liang; Gina N. Duronio; Yaying Yang; Pratyusha Bala; Prajna Hebbar; Sandor Spisak; Pranshu Sahgal; Harshabad Singh; Yanxi Zhang; Yingtian Xie; Paloma Cejas; Henry W. Long; Adam J. Bass; Nilay S. Sethi
• Keywords: 0301 basic medicine; Genes, APC; Cell Differentiation; Mice, Transgenic; SOX9 Transcription Factor; Tumor Burden; 3. Good health; Gene Expression Regulation, Neoplastic; 03 medical and health sciences; Enhancer Elements, Genetic; Neoplastic Stem Cells; Tumor Cells, Cultured; Animals; Humans; AC133 Antigen; Colorectal Neoplasms; HT29 Cells; Wnt Signaling Pathway; Cell Proliferation

Genomic alterations that encourage stem cell activity and hinder proper maturation are central to the development of colorectal cancer (CRC). Key molecular mediators that promote these malignant properties require further elucidation to galvanize translational advances. We therefore aimed to characterize a key factor that blocks intestinal differentiation, define its transcriptional and epigenetic program, and provide preclinical evidence for therapeutic targeting in CRC.Intestinal tissue from transgenic mice and patients were analyzed by means of histopathology and immunostaining. Human CRC cells and neoplastic murine organoids were genetically manipulated for functional studies. Gene expression profiling was obtained through RNA sequencing. Histone modifications and transcription factor binding were determined with the use of chromatin immunoprecipitation sequencing.We demonstrate that SRY-box transcription factor 9 (SOX9) promotes CRC by activating a stem cell-like program that hinders intestinal differentiation. Intestinal adenomas and colorectal adenocarcinomas from mouse models and patients demonstrate ectopic and elevated expression of SOX9. Functional experiments indicate a requirement for SOX9 in human CRC cell lines and engineered neoplastic organoids. Disrupting SOX9 activity impairs primary CRC tumor growth by inducing intestinal differentiation. By binding to genome wide enhancers, SOX9 directly activates genes associated with Paneth and stem cell activity, including prominin 1 (PROM1). SOX9 up-regulates PROM1 via a Wnt-responsive intronic enhancer. A pentaspan transmembrane protein, PROM1 uses its first intracellular domain to support stem cell signaling, at least in part through SOX9, reinforcing a PROM1-SOX9 positive feedback loop.These studies establish SOX9 as a central regulator of an enhancer-driven stem cell-like program and carry important implications for developing therapeutics directed at overcoming differentiation defects in CRC.